We were delighted to meet with Martin Hoenigl (University of California San Diego & Medical University of Graz, Graz, Austria) to discuss the current challenges in treating invasive candida infections.
The abstract entitled: ‘Outcomes of oral ibrexafungerp in 33 patients with refractory fungal diseases, interim analysis of a phase III open-label study (FURI)’ was presented at the 31st European Congress of Clinical Microbiology & Infectious Diseases (ECCMID).
- Could you give us a brief overview of the current challenges in treating invasive Candida infections? (0:22)
Disclosures: Martin Hoenigl has received research support from Gilead, Astellas, Pfizer, Scynexis, F2G and NIH.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Filmed in coverage of the 31st ECCMID Congress 2021.
Share this Video
Related Videos In Bacterial and Fungal Infections
Jinhee Jo, IDWeek 2021: Global Surveillance of Clostridioides difficile
It was a pleasure to meet with Dr Jinhee Jo (Department of Pharmacy Practice and Translational Research, University of Houston, Houston, TX, USA) to discuss her study investigating the understanding of how C. Difficile is transmitted, and who it affects. The abstract entitled: ‘Global Surveillance of Clostridioides difficile Demonstrates High Prevalence in Non-Healthcare Settings’ was […]
Kevin Garey, IDWeek 2021: Health-related Quality of Life Findings from the ECOSPOR Phase 3 Trial
It was a pleasure to meet with Prof. Kevin Garey (University of Houston College of Pharmacy, Houston, TX, USA) to discuss the results from the ECOSPOR phase 3 trial, and how SER-109 impacts patients’ health-related quality of life. Watch Part 1 of this interview here. The abstract entitled: ‘The Impact of Investigational Purified Microbiome Therapeutic […]
Kevin Garey, IDWeek 2021: Limitations of Current Treatment Approaches for Recurrent C difficile Infections
We had the great pleasure of meeting with Prof. Kevin Garey (University of Houston College of Pharmacy, Houston, TX, USA) to discuss the health burden of C difficile infections, and the limitations of current treatment approaches. Watch Part 2 of the interview here. The abstract entitled: ‘The Impact of Investigational Purified Microbiome Therapeutic SER-109 on […]
Journal articles and more to your inbox
Get the latest clinical insights from touchINFECTIOUS DISEASESSign me up!